Floatz logo

10 assets in Ovarian Transitional Cell Carcinoma

Therapeutic assets addressing Ovarian Transitional Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Carboplatin
Ovarian Transitional Cell Carcinoma
National Cancer Institute (NCI)P3BBB (72)
Adriamycin
Ovarian Transitional Cell Carcinoma
National Cancer Institute (NCI)P3BB (71)
Cediranib
Ovarian Transitional Cell Carcinoma
National Cancer Institute (NCI)P3BB (69)
Olaparib
Ovarian Transitional Cell Carcinoma
National Cancer Institute (NCI)P3BB (68)
Nogitecan
Ovarian Transitional Cell Carcinoma
National Cancer Institute (NCI)P2/3BB (64)
Docetaxel
Ovarian Transitional Cell Carcinoma
National Cancer Institute (NCI)P3B (60)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Ovarian Transitional Cell Carcinoma
Mayo ClinicP2B (59)
Durvalumab
Ovarian Transitional Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Ovarian Transitional Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Nivolumab
Ovarian Transitional Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)